SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics Monthly Activity About

SEC Comment Letter for Westin Acquisition Corp (WSTN, WSTNR, WSTNU) (CIK 0002076192) (WSTN) — Aug 29, 2025

Westin Acquisition Corp (WSTN, WSTNR, WSTNU) (CIK 0002076192)
Date: Aug. 29, 2025 · CIK: 0002076192 · Accession: 0000000000-25-009315

Capital Structure Regulatory Compliance Business Model Clarity

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288889

Date
August 29, 2025
Author
Kok Peng Na
Form
UPLOAD
Company
Westin Acquisition Corp (WSTN, WSTNR, WSTNU) (CIK 0002076192)

Letter

August 29, 2025 Kok Peng Na Chief Executive Officer Westin Acquisition Corp Suite 1165-L 3 Coleman Street #03-24 Singapore 179804 Re:Westin Acquisition Corp Amendment No. 1 to Registration Statement on Form S-1 Filed August 25, 2025 File No. 333-288889 Dear Kok Peng Na: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Amendment No. 1 to Registration Statement on Form S-1 Prospectus Summary, page 1 1.We note your response to prior comment 2 and reissue. Disclosure on the cover, and elsewhere in your prospectus, indicates that only Class B shareholders will have the right to vote to appoint and remove directors prior to, or in connection with, the completion of your initial business combination and only they will vote on continuing your company in a jurisdiction outside the Cayman Islands. Please revise your prospectus summary to highlight your dual-class capital structure addressing the disparate voting rights of the Class A and Class B ordinary shares. Please contact Bonnie Baynes at 202-551-4924 or Daniel Gordon at 202-551-3486 if you have questions regarding comments on the financial statements and related matters. Please contact Tyler Howes at 202-551-3370 or Chris Edwards at 202-551-6761

August 29, 2025 Page 2 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Cassi Olson, Esq.

Show Raw Text
August 29, 2025
Kok Peng Na
Chief Executive Officer
Westin Acquisition Corp
Suite 1165-L 3 Coleman Street #03-24
Singapore 179804
Re:Westin Acquisition Corp
Amendment No. 1 to Registration Statement on Form S-1
Filed August 25, 2025
File No. 333-288889
Dear Kok Peng Na:
            We have reviewed your amended registration statement and have the following
comment.
            Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments.
Amendment No. 1 to Registration Statement on Form S-1
Prospectus Summary, page 1
1.We note your response to prior comment 2 and reissue. Disclosure on the cover, and
elsewhere in your prospectus, indicates that only Class B shareholders will have the
right to vote to appoint and remove directors prior to, or in connection with, the
completion of your initial business combination and only they will vote on continuing
your company in a jurisdiction outside the Cayman Islands. Please revise your
prospectus summary to highlight your dual-class capital structure addressing the
disparate voting rights of the Class A and Class B ordinary shares.
            Please contact Bonnie Baynes at 202-551-4924 or Daniel Gordon at 202-551-3486 if
you have questions regarding comments on the financial statements and related
matters. Please contact Tyler Howes at 202-551-3370 or Chris Edwards at 202-551-6761

August 29, 2025
Page 2
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Cassi Olson, Esq.